Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patientsChristoph Suppan, Marija Balić, Ricarda Graf et al.|British Journal of Cancer|2021Cited by 34
Addition of the MUC-1 vaccine tecemotide to neoadjuvant systemic therapy for patients with early breast cancer: Survival results from the prospective randomized ABCSG 34 trial.Christian F. Singer, Michael Gnant, Lidija Soelkner et al.|Journal of Clinical Oncology|2024Cited by 6
New Perspectives in the Management of Triple-Negative Breast CancerRupert Bartsch, Michael Gnant, Zsuzsanna Bagó-Horváth et al.|Breast Care|2025Cited by 3
HER2 and HER3 expression during neoadjuvant treatment of HER2‐negative early breast cancer: potential for biomarker‐driven sequencing of T‐DXd and HER3‐DXdChristian F. Singer, Stephan Jahn, Dominik Hlauschek et al.|癌症：英文版|2025Cited by 3
Prospective randomized phase II trial to assess the efficacy and safety of neo-adjuvant olaparib/carboplatin (OC) in comparison to docetaxel/epirubicin/cyclophosphamide (TAC) in patients with early triple-negative breast cancer (TNBC) with homologous recombination deficiency (HRD): Primary results from the ABCSG 45 trial.Christian F. Singer, Michael Gnant, Dominik Hlauschek et al.|Journal of Clinical Oncology|2025Cited by 3